Nucleic Acids Research Advance Access originally published online on March 5, 2007
Nucleic Acids Research 2007 35(7):e49; doi:10.1093/nar/gkm053
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nucleic Acids Research, 2007, Vol. 35, No. 7 e49
© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Methods Online |
A non-covalent peptide-based carrier for in vivo delivery of DNA mimics
1Centre de Recherches en Biochimie Macromoléculaire, Department of Molecular Biophysics and Therapeutics, FRE-2593 CNRS, 1919 Route de Mende, 34293 Montpellier, France and 2Active Motif, Carlsbad, California, USA
*To whom correspondence should be addressed. Tel: +33 04 67 61 33 92; Fax: +33 04 67 52 15 59; Email: gilles.divita{at}crbm.cnrs.fr
Received October 4, 2006. Revised January 16, 2007. Accepted January 17, 2007.
The dramatic acceleration in identification of new nucleic-acid-based therapeutic molecules has provided new perspectives in pharmaceutical research. However, their development is limited by their poor cellular uptake and inefficient trafficking. Here we describe a short amphipathic peptide, Pep-3, that combines a tryptophan/phenylalanine domain with a lysine/arginine-rich hydrophilic motif. Pep-3 forms stable nano-size complexes with peptide-nucleic acid analogues and promotes their efficient delivery into a wide variety of cell lines, including primary and suspension lines, without any associated cytotoxicity. We demonstrate that Pep-3-mediated delivery of antisense-cyclin B1-charged-PNA blocks tumour growth in vivo upon intratumoral and intravenous injection. Moreover, we show that PEGylation of Pep-3 significantly improves complex stability in vivo and consequently the efficiency of antisense cyclin B1 administered intravenously. Given the biological characteristics of these vectors, we believe that peptide-based delivery technologies hold a true promise for therapeutic applications of DNA mimics.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. Crombez, M. C. Morris, S. Dufort, G. Aldrian-Herrada, Q. Nguyen, G. Mc Master, J.-L. Coll, F. Heitz, and G. Divita Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth Nucleic Acids Res., August 1, 2009; 37(14): 4559 - 4569. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shiraishi, R. Hamzavi, and P. E. Nielsen Subnanomolar antisense activity of phosphonate-peptide nucleic acid (PNA) conjugates delivered by cationic lipids to HeLa cells Nucleic Acids Res., August 1, 2008; 36(13): 4424 - 4432. [Abstract] [Full Text] [PDF] |
||||
